Trials / Completed
CompletedNCT06604624
Semaglutide in Treatment of Obesity
To Evaluate a Multicenter, Randomized, Open, Positive Parallel Controlled Phase III Clinical Trial of Semaglutide Injection (HD1916) in the Treatment of Obesity
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 462 (actual)
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, open, positive parallel controlled phase III clinical trial to compare the efficacy and safety of once-weekly HD1916 and semaglutide injection and to evaluate immunogenicity in obese non-diabetic adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HD1916 | HD1916，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week |
| DRUG | semaglutide | semaglutide ，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week |
Timeline
- Start date
- 2024-09-20
- Primary completion
- 2025-08-27
- Completion
- 2025-09-24
- First posted
- 2024-09-19
- Last updated
- 2026-04-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06604624. Inclusion in this directory is not an endorsement.